Ammonia levels after asparaginase in children
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how many children develop high ammonia levels after receiving a cancer medicine called recombinant Erwinia asparaginase. It helps doctors understand side effects and keep patients safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 1 year old or older.
- You are being treated by a pediatric blood cancer doctor (pediatric hematology/oncology).
- You are currently receiving a medicine called recombinant Erwinia asparaginase for your cancer.
- You have not received this same medicine in the past two weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a chemotherapy drug called calaspargase pegol affects blood clotting in children and young adults with leukemia. It will help doctors understand if changes in clotting are common and safe.
This study looks at how long the chemotherapy medicine calaspargase stays active in the body. It may help doctors understand how to dose this medicine better for future patients.
This study looks at how the immune system (T cells and B cells) responds to a common chemotherapy drug called asparaginase. It aims to understand why some children develop antibodies against the drug, which may cause allergic reactions and reduce effectiveness, to help improve future treatments.
This study looks at why some patients have allergic reactions to asparaginase, a chemotherapy drug used to treat acute lymphoblastic leukemia. By studying blood samples taken before the consolidation phase, researchers hope to find ways to predict and manage these reactions.
This study looks at how a common chemotherapy drug called asparaginase affects people in real life. It aims to understand side effects better so doctors can improve care for patients with leukemia or lymphoma.
This trial looks at how a medicine called asparaginase affects blood clotting in children treated for acute lymphoblastic leukaemia (a type of blood cancer). It may help doctors better manage bleeding or clot risks during treatment.
Hear when a new Hematopoietic and Lymphatic System Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.